CORONA Remedies Limited has informed the Exchange that Board of Directors at its meeting held on May 11, 2026, recommended Final Dividend of Rs. 10 per equity share.
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CORONA Remedies Limited's Board meeting on May 11, 2026 approved audited financial results for Q4 and FY2026. Standalone net profit grew to Rs. 184.85 Crores from Rs. 149.05 Crores year-over-year, while revenue from operations increased to Rs. 1,403.18 Crores from Rs. 1,196.42 Crores, representing approximately 17% revenue growth. The Board recommended a final dividend of Rs. 10 per equity share (100% of face value), payable after shareholder approval at the AGM. Record date is June 19, 2026, and dividend will be paid by August 7, 2026. The company also appointed Walker Chandiok & Co LLP as statutory auditor for 5 years. An exceptional charge of Rs. 19.10 Crores was recorded due to one-time impact of new Labour Codes. The company listed on NSE and BSE in December 2025 via an IPO.
The company demonstrates strong earnings growth and a 100% dividend payout, which is positive for income-focused investors. However, the dividend yield remains low given the recent IPO price of Rs. 1,062 per share.